ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, ACAD could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
ACAD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ACAD reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 20.23%, ACAD belongs to the best of the industry, outperforming 97.49% of the companies in the same industry.
With an excellent Return On Equity value of 29.93%, ACAD belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
The Return On Invested Capital of ACAD (9.30%) is better than 94.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| ROIC | 9.3% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 22.99%, ACAD belongs to the best of the industry, outperforming 95.69% of the companies in the same industry.
ACAD has a Operating Margin of 8.84%. This is amongst the best in the industry. ACAD outperforms 93.72% of its industry peers.
With an excellent Gross Margin value of 92.08%, ACAD belongs to the best of the industry, outperforming 93.18% of the companies in the same industry.
ACAD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.84% | ||
| PM (TTM) | 22.99% | ||
| GM | 92.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ACAD has an Altman-Z score of 4.75. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.75, ACAD is in the better half of the industry, outperforming 77.02% of the companies in the same industry.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.75 |
ROIC/WACC0.96
WACC9.68%
2.3 Liquidity
ACAD has a Current Ratio of 2.87. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD has a Current ratio of 2.87. This is in the lower half of the industry: ACAD underperforms 66.25% of its industry peers.
A Quick Ratio of 2.80 indicates that ACAD has no problem at all paying its short term obligations.
With a Quick ratio value of 2.80, ACAD is not doing good in the industry: 64.81% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 5000.00%, which is quite impressive.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 22.39%.
The Revenue has been growing by 23.08% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.65% yearly.
The Revenue is expected to grow by 10.99% on average over the next years. This is quite good.
EPS Next Y17.36%
EPS Next 2Y35.61%
EPS Next 3Y45.23%
EPS Next 5Y44.65%
Revenue Next Year9.35%
Revenue Next 2Y9.97%
Revenue Next 3Y10.61%
Revenue Next 5Y10.99%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 42.61, ACAD can be considered very expensive at the moment.
ACAD's Price/Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 92.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of ACAD to the average of the S&P500 Index (27.29), we can say ACAD is valued expensively.
A Price/Forward Earnings ratio of 23.65 indicates a rather expensive valuation of ACAD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.56% of the companies listed in the same industry.
ACAD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.74, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.61 | ||
| Fwd PE | 23.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaply inside the industry as 92.28% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaply inside the industry as 91.92% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 70.62 | ||
| EV/EBITDA | 35.45 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
ACAD's earnings are expected to grow with 45.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.45
PEG (5Y)N/A
EPS Next 2Y35.61%
EPS Next 3Y45.23%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.88
-0.07 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.58%
Inst Owner Change0%
Ins Owners0.31%
Ins Owner Change3.85%
Market Cap3.49B
Analysts76.15
Price Target27.54 (31.9%)
Short Float %9.31%
Short Ratio6.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.13%
Min EPS beat(2)-109.07%
Max EPS beat(2)-3.19%
EPS beat(4)2
Avg EPS beat(4)-15.12%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)7
Avg EPS beat(12)13.32%
EPS beat(16)10
Avg EPS beat(16)17.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)0.08%
Revenue beat(4)2
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.72%
Revenue beat(16)7
Avg Revenue beat(16)-1.86%
PT rev (1m)11.52%
PT rev (3m)8.69%
EPS NQ rev (1m)-2.3%
EPS NQ rev (3m)-18.19%
EPS NY rev (1m)-5.17%
EPS NY rev (3m)-14.8%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.61 | ||
| Fwd PE | 23.65 | ||
| P/S | 3.51 | ||
| P/FCF | 70.62 | ||
| P/OCF | 23.45 | ||
| P/B | 4.57 | ||
| P/tB | 5.39 | ||
| EV/EBITDA | 35.45 |
EPS(TTM)0.49
EY2.35%
EPS(NY)0.88
Fwd EY4.23%
FCF(TTM)0.3
FCFY1.42%
OCF(TTM)0.89
OCFY4.26%
SpS5.95
BVpS4.57
TBVpS3.87
PEG (NY)2.45
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| ROCE | 10.62% | ||
| ROIC | 9.3% | ||
| ROICexc | 9.3% | ||
| ROICexgc | 10.83% | ||
| OM | 8.84% | ||
| PM (TTM) | 22.99% | ||
| GM | 92.08% | ||
| FCFM | 4.97% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 151.14% | ||
| Profit Quality | 21.61% | ||
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 4.75 |
F-Score5
WACC9.68%
ROIC/WACC0.96
Cap/Depr(3y)241.2%
Cap/Depr(5y)203.04%
Cap/Sales(3y)1.85%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y17.36%
EPS Next 2Y35.61%
EPS Next 3Y45.23%
EPS Next 5Y44.65%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
Revenue Next Year9.35%
Revenue Next 2Y9.97%
Revenue Next 3Y10.61%
Revenue Next 5Y10.99%
EBIT growth 1Y1912.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.12%
EBIT Next 3Y44.84%
EBIT Next 5Y49.94%
FCF growth 1Y188.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y367.79%
OCF growth 3YN/A
OCF growth 5YN/A